COMBINING BASELINE TOTAL METABOLIC TUMOR VOLUME AND BETA‐2‐MICROGLOBULIN LEVELS PREDICTS OUTCOMES IN HIGH BURDEN FOLLICULAR LYMPHOMA

Introduction: Follicular lymphoma (FL) usually presents an indolent course with repeated events of disease progression but treatment-free time intervals and patients’ survival are reduced at each relapse. Many prognostic scores exist few used in practice due to their complexity. Total metabolic tumor volume (TMTV) has demonstrated a strong value FL its routine use is increasing academic centers. We aim explore the predictive simple score based on TMTV beta-2-microglobulin (B2M) levels baseline high burden identify patients highest unmet medical need. Methods: In this monocentric retrospective analysis, we enrolled adult admitted our hospital between 2006 2018 fulfilling following inclusion criteria: grade 1 3A least one criteria defined by Groupe d'Etude des Lymphomes Folliculaires (GELF), available PET-CT images collected before first-line standard immunochemotherapy start suitable for assessment. Baseline was determined using 41% SUVmax threshold method. B2M were routinely measured diagnosis. Primary endpoints progression-free (PFS) overall (OS) according combining B2M. Results: included 126 analysis. Median age treatment 61 years (55; 57). Patients displayed advanced-stage (n = 112, 88.9%), intermediate 51, 40.8%) or 62, 49.6%) FLIPI 40, 33.3%) 31, 25.8%) PRIMA-PI scores. 12.1 (10; 17) 606 mm3 (268;1219), respectively. 125 (97%) >3 mg/L 30 (24%). Treatment regimens mostly R-CHOP like 109, 86.5%) R-lenalidomide 9, 7.1%). 80 (63.5%) received maintenance therapy during 24 months. three risk categories : (i) Low 45, 36%): ≤510 ≤3 mg/L; (ii) Intermediate 57, 45.6%) >510 ; (iii) High 23, 18.4%) mg/L. With median follow-up 83 (52; 116) months, 5-year PFS 81.7% (95% CI: 71–94), 53.7% 41.8–69) 38.6% 23–65) low, groups, respectively (p < 0.0001). Five-year OS 14 deaths estimated 96.1% 91–100), 89.1% 81.2–97.7) 73.7% 57.6–94.2) 0.003). Keywords: aggressive B-cell non-Hodgkin lymphoma, diagnostic biomarkers, No conflicts interests pertinent abstract.